These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26944649)

  • 1. [Not Available].
    Bourgeois F
    Rev Infirm; 2016 Mar; (219):45-6. PubMed ID: 26944649
    [No Abstract]   [Full Text] [Related]  

  • 2. Equivalence of Glatiramer Acetate Generics With Branded Glatiramer Acetate in Efficacy and Cost for the Treatment of Multiple Sclerosis.
    Bourdette D; Hartung D
    JAMA Neurol; 2015 Dec; 72(12):1411-3. PubMed ID: 26457848
    [No Abstract]   [Full Text] [Related]  

  • 3. Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?
    Sørensen PS
    Nat Rev Neurol; 2016 Jan; 12(1):5-6. PubMed ID: 26635211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple sclerosis disease-modifying therapy and pregnancy.
    Miller AE
    Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870
    [No Abstract]   [Full Text] [Related]  

  • 6. [In process].
    Verspohl EJ
    Med Monatsschr Pharm; 2017 Jan; 40(1):40. PubMed ID: 29952537
    [No Abstract]   [Full Text] [Related]  

  • 7. Demonstration of equivalence of a generic glatiramer acetate (Glatopa™).
    Anderson J; Bell C; Bishop J; Capila I; Ganguly T; Glajch J; Iyer M; Kaundinya G; Lansing J; Pradines J; Prescott J; Cohen BA; Kantor D; Sachleben R
    J Neurol Sci; 2015 Dec; 359(1-2):24-34. PubMed ID: 26671082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease modifying therapies in multiple sclerosis: could a baseline thyroid check-up drive the therapeutic choice between interferon-β and glatiramer acetate?
    Rotondi M; Bergamaschi R; Chiovato L
    Mult Scler; 2014 Dec; 20(14):1918-9. PubMed ID: 24812044
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?
    Garattini L; Ghislandi F; Da Costa MR
    Pharmacoeconomics; 2015 Dec; 33(12):1241-4. PubMed ID: 26293887
    [No Abstract]   [Full Text] [Related]  

  • 10. The emergence of follow-on disease-modifying therapies for multiple sclerosis.
    Moss BP; Cohen JA
    Mult Scler; 2019 Oct; 25(12):1560-1565. PubMed ID: 31074707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant multiple sclerosis and polycythemia vera successfully treated with glatiramer acetate.
    Krečak I; Celić-Bunikić S; Skelin M; Lucijanić M; Verstovsek S; Kušec R
    Ann Hematol; 2022 Aug; 101(8):1885-1886. PubMed ID: 35461396
    [No Abstract]   [Full Text] [Related]  

  • 12. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P; Lucisano G; Pozzilli C; Brescia Morra V; Ghezzi A; Millefiorini E; Patti F; Lugaresi A; Zimatore GB; Marrosu MG; Amato MP; Bertolotto A; Bergamaschi R; Granella F; Coniglio G; Tedeschi G; Sola P; Lus G; Ferrò MT; Iuliano G; Corea F; Protti A; Cavalla P; Guareschi A; Rodegher M; Paolicelli D; Tortorella C; Lepore V; Prosperini L; Saccà F; Baroncini D; Comi G; Trojano M;
    Brain; 2015 Nov; 138(Pt 11):3275-86. PubMed ID: 26362907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition.
    Hasson T; Kolitz S; Towfic F; Laifenfeld D; Bakshi S; Beriozkin O; Shacham-Abramson M; Timan B; Fowler KD; Birnberg T; Konya A; Komlosh A; Ladkani D; Hayden MR; Zeskind B; Grossman I
    J Neuroimmunol; 2016 Jan; 290():84-95. PubMed ID: 26711576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis.
    Burke T; Hooper K; Barlow S; Hatter L
    Aust Nurs Midwifery J; 2013 Nov; 21(5):30-3. PubMed ID: 24672970
    [No Abstract]   [Full Text] [Related]  

  • 15. Glatiramer acetate-induced hepatitis in a patient with multiple sclerosis.
    Flaire A; Carra-Dalliere C; Ayrignac X; Blanc P; Labauge P
    Acta Neurol Belg; 2016 Mar; 116(1):99-100. PubMed ID: 26141739
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
    Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M;
    Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychiatric manifestations in multiple sclerosis patients and multiple sclerosis in psychiatric patient.
    Fragoso YD; Brooks JB
    Arq Neuropsiquiatr; 2009 Dec; 67(4):1167-8. PubMed ID: 20069241
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple sclerosis in childhood: understanding and caring for children with an "adult" disease.
    Boyd JR; MacMillan LJ
    Axone; 2000 Dec; 22(2):15-21. PubMed ID: 11901486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New active substances expand the treatment options for MS].
    Hellwig B
    Med Monatsschr Pharm; 2015 Feb; 38(2):65-8. PubMed ID: 26376542
    [No Abstract]   [Full Text] [Related]  

  • 20. The effectiveness of glatiramer acetate in clinical practice: an observational study.
    Fernández-Fernández Ó; Garcia-Trujillo L; Guerrero-Fernández M; León A; López-Madrona JC; Alonso A; Bustamante R; Fernández-Sánchez VE
    Rev Neurol; 2012 Jan; 54(1):1-9. PubMed ID: 22187206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.